Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised OHB AG on its acquisition of the Space Systems Division from the Swedish Space Corporation
Mandate

Vinge advised OHB AG on its acquisition of the Space Systems Division from the Swedish Space Corporation

September 08, 2011

Vinge advised OHB AG in connection with the acquisition of the Space Systems Division from the Swedish Space Corporation (SSC). The division is an industrial partner of the Swedish National Space Board and the European Space Agency (ESA) and involved in the development and construction of satellite and payload systems. OHB AG is a German aerospace and technology company listed on the Frankfurt Stock Exchange.

The transaction was led by partner Christina Kokko with assistance from Associates Matthias Pannier, Paul Dali, Louise Markgren, Daniel Järmén, Fredrik Gustafsson, Nicklas Thorgerzon and project assistant Annica Sedvall.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026